CN EN JP
{pboot:sort scode=} [sort:name]
[sort:name]
{/pboot:sort}
{pboot:sort scode=}[sort:name]{/pboot:sort}
2026.04.28NMPA Approves Phase I Clinical Trial Application for New Indication of Anti-Allergy Desensitization Drug ZHB118 Sublingual Tablets
On April 27, 2026, ZonhonBio's independently developed Class 1 novel biologic drug ZHB118 subl···
2026.04.28NMPA Approves Phase I Clinical Trial Application for New Indication of Anti-Allergy Desensitization Drug ZHB117 Sublingual Tablets
On April 27, 2026, ZonhonBio's independently developed Class 1 novel biologic drug ZHB117 subl···
2026.02.13THE 2025 ANNUAL MEETING AND 2026 NEW YEAR PARTY OF ZONHONBIO AND GENSUNBIO HELD SUCCESSFULLY
As the new spring arrives with the galloping Year of the Horse, the 2025 annual meeting and 2026 New···
2025.12.11Allergy Desensitization Drugs ZHB107-108 Sublingual Tablets Complete Phase I Clinical Trial with Summary Report Issued
Recently, ZonhonBio completed a Phase I clinical trial for its "ZHB107-108 Sublingual Tablets···
2025.12.10Implementation of Phase I Clinical Trial Application for Anti-Allergy Desensitization Drug ZHB117 Sublingual Tablets
On December 10, 2025, ZonhonBio initiated the Phase I clinical trial of ZHB117 Sublingual Tablet···
2025.12.10Implementation of Phase I Clinical Trial Application for Anti-Allergy Desensitization Drug ZHB 118 Sublingual Tablets
On December 10, 2025, ZonhonBio initiated the Phase I clinical trial of ZHB118 Sublingual Tablets—an···
2025.09.20The New Indication Phase I Clinical Trial Application for the Anti-Allergy Desensitization Drug ZHB110 Sublingual Tablets has been Approved by the National Medical Products Administration
On September 19, 2025, Zonhonbio's original Category 1 therapeutic biological new drug ZHB110 ···
2025.08.26Zonhonbio’s 14th Anniversary Celebration and 2025 Zonhonbio & Gensunbio R&D Achievements Reports Conference Successfully Held
August 25, 2025 marked ZonhonBio's 14th anniversary, with the "2025 Zonhonbio & Gensunb···